NCT07264075
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07264075
Title Study Comparing Ivonescimab Alone or Ivonescimab in Combination With Ligufalimab Versus Pembrolizumab for the Treatment of SCCHN (ILLUMINE)
Acronym ILLUMINE
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Groupe Oncologie Radiotherapie Tete et Cou
Indications
Therapies
Age Groups: adult | senior
Covered Countries FRA


No variant requirements are available.